Abstract Library

#4534 Development of new 3D in vitro models for pancreatic neuroendocrine tumours (PanNETs)

Introduction: Current PanNET in vitro models struggle to accurately replicate the tumour’s biology and microenvironment, limiting understanding of the mechanisms underlying PanNET behaviour and drugs response.

Conference:

Presenting Author:

Authors: Battistella A, Pinos R, Barbaglio F, Capurso G, Schiavo Lena M,

Keywords: Preclinical models, Pan NET, microenvironment, bioprinting, tumour slices, drug testing,

#4519 ANXA1-labelled cancer-associated fibroblasts induces tumour invasion and immunosuppressive microenvironment

Introduction: The growth pattern of a tumour is a marker for distinguishing inert from invasive tumours. In general, tumours such as the encapsulated follicular variant of papillary thyroid carcinoma show expansive growth. In contrast, invasive tumours, such as colorectal cancer and squamous cell carcinoma of the tongue, show invasive growth with infiltration into surrounding structures and have a poorer prognosis. Pancreatic neuroendocrine neoplasm (PNEN) is the heterogeneous tumour originating from peptidergic neurons and neuroendocrine cells. PNEN with a high proportion of tumour mesenchyme, especially those presenting an infiltrating stroma, have a poor prognosis. In the infiltrating mesenchyme, cancer-associated fibroblasts (CAF) play an important role. However, little research has been done on the mechanisms of how infiltrating CAF affects tumour malignancy and immune microenvironment.

Conference:

Presenting Author: Wang Y

Authors: Wang Y, Xu J, Chen J, Xu X, Ji S,

Keywords: pancreatic neuroendocrine neoplasm, tumour-associated fibroblasts, immunosuppressive microenvironment,

#4476 Pancreatic stellate cells promote tumorigenesis and progression of pancreatic neuroendocrine tumours through SERPINE2 and KCNA5

Introduction: Pancreatic stellate cells (PSC) are stromal cells in the pancreas that play a significant role in pancreatic pathology. Nevertheless, few studies have explored the significance of PSC in pancreatic neuroendocrine tumours (panNET). Their contribution to the fibrotic responses in panNET remains poorly understood. How PSC promote tumorigenesis and differentiation in panNET after being activated to myofibroblasts or cancer-associated fibroblasts (CAF) has not been studied.

Conference:

Presenting Author: Tang Q

Authors: Liu J, Li X, Bai J, Tang Q,

Keywords: caf, stellate cell, pan NET, Oncogenes,

#4424 Tumour-derived apolipoprotein E induces tip endothelial cell to remodel tumour stroma ratio and promote pancreatic neuroendocrine tumour progression

Introduction: Current clinical trials have shown that single-targeted matrix administration does not improve patient prognosis. The investigation of targeted matrix administration in combination with other therapies is crucial for effectively managing TSR in pNETs.

Conference:

Presenting Author: Ji S

Authors: Lou X, Ji S, Xu X, Chen J, Yu X,

Keywords: APOE, pancreatic neuroendocrine tumour, endothelial cell, tumour stroma ratio, mTOR inhibitor,

#4207 START-NET: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors – An open-label, multi-center, randomised phase III trial comparing safety and efficacy of personalised vs non-personalised radionuclide therapy with 177Lu-DOTATOC

Introduction: Peptide receptor radionuclide therapy (PRRT) with fixed activity dosing is an established treatment for advanced neuroendocrine tumors (NETs). Emerging data suggest that patients may benefit from a personalized treatment approach. Aggressive NET is believed to benefit from more intensive treatment, one example being FDG-PET positive tumors have shown benefit from combining PPRT with chemotherapy. Dosimetry is another means of achieving personalisation and can be used to increase the tumor radiation doses without surpassing the toxicity limits of organs at risk.

Conference:

Presenting Author: Asp P

Authors: Asp P, Sjögreen-Gleisner K, Fröss-Baron K, Sandström M, Hallqvist A,

Keywords: NET, PRRT, dosimetry, PET, 177Lu-DOTATOC, capecitabine,